Neuronetics, Inc., the medical device company that introduced the NeuroStar TMS (transcranial magnetic stimulation) Therapy system, has announced that Mark Saxton, an industry executive with more than 18 years of experience in sales leadership, has been appointed as vice president of sales and customer service.
In his new role, Saxton will manage sales and customer relations as well as oversee the development and execution of related commercialization strategies for NeuroStar TMS Therapy, a non-invasive neuromodulation treatment for adults with major depressive disorder who have not benefitted from initial antidepressant medication.
“Mark brings an exceptional track record of delivering sales results and satisfying customers, and we are pleased to welcome him to our senior management team,” said Bruce Shook, president and CEO of Neuronetics. “We are confident that Mark’s skill with sales and practice development will accelerate revenue growth and build substantial value here at Neuronetics.”
Prior to joining Neuronetics, Saxton served as a vice president of sales for Covidien, a global healthcare products leader dedicated to creating innovative medical solutions. His experience at Covidien followed a lengthy career with VNUS Medical, which pioneered the market for minimally invasive treatment of varicose veins.
The team at VNUS redefined the standard of care for this disorder and moved it from an invasive and traumatic surgical procedure to an office based treatment that was adopted by multiple medical specialties. As vice president of sales, Saxton led VNUS to substantial sales growth, resulting in their acquisition by Covidien in 2009.
Prior to his 10 years with VNUS and Covidien, Saxton held sales positions of increasing responsibility with InnerDyne Medical, Inc., a medical device maker that specializes in instruments for minimally invasive surgery, and PMT Corp., a manufacturer of products for neurosurgery, orthopedics and plastic and reconstructive surgery.
“Neuronetics has just begun to tap the market for NeuroStar TMS Therapy. The potential for growth is tremendous, and I welcome the opportunity to take the company to the next level of customer satisfaction,” said Saxton. “My experience helping physicians adopt new treatments that improve patient care is directly applicable to the current stage of the business at Neuronetics. I am delighted to promote a product that will positively impact the lives of so many people.”